What is HC Wainwright’s Estimate for OCUL FY2027 Earnings?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Ocular Therapeutix in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will earn ($1.51) per share for the year. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.29) per share.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 558.24% and a negative return on equity of 71.22%. The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same period in the prior year, the company posted ($0.29) EPS. The company’s revenue was down 22.4% on a year-over-year basis.

A number of other research firms have also commented on OCUL. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Monday, March 2nd. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL opened at $9.71 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. Ocular Therapeutix has a 52-week low of $6.23 and a 52-week high of $16.44. The firm has a 50 day moving average price of $9.07 and a two-hundred day moving average price of $10.53. The stock has a market cap of $2.13 billion, a P/E ratio of -6.65 and a beta of 0.93.

Insider Buying and Selling at Ocular Therapeutix

In related news, COO Donald Notman sold 11,446 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $103,471.84. Following the transaction, the chief operating officer directly owned 366,356 shares of the company’s stock, valued at $3,311,858.24. This represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 124,882 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the completion of the transaction, the insider directly owned 3,033,078 shares in the company, valued at $27,419,025.12. This trade represents a 3.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 185,731 shares of company stock valued at $1,653,407 over the last 90 days. Insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Summer Road LLC lifted its stake in shares of Ocular Therapeutix by 6.9% in the first quarter. Summer Road LLC now owns 11,879,825 shares of the biopharmaceutical company’s stock valued at $100,622,000 after buying an additional 771,270 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Ocular Therapeutix by 26.3% in the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after buying an additional 2,411,953 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Ocular Therapeutix by 5.1% in the fourth quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company’s stock valued at $130,842,000 after buying an additional 527,777 shares in the last quarter. TCG Crossover Management LLC raised its holdings in shares of Ocular Therapeutix by 15.0% in the third quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock valued at $71,510,000 after purchasing an additional 798,084 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Ocular Therapeutix by 15.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company’s stock valued at $56,148,000 after purchasing an additional 620,700 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.